메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01). The trial is evaluating the company's developed IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) as a first-line
- 김갑성 기자
- 2026-02-13 08:00
Waters, BD 생명과학 및 진단 솔루션 사업 부문과의 합병 성사

Claire M. Fraser 박사를 이사회 이사로 신규 선임 규제 환경에서의 고처리량 시험에 특화된 글로벌 생명과학 및 진단 분야 선도 기업으로 도약 4개 사업부 신설 발표: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, Waters Materials Sciences 매사추세츠주 밀퍼드, 2026년 2월 13일 -- Waters Corporation(NYSE: WAT)(이하 "Waters")은 오늘 Becton, Dickinson and Company(NYSE: BDX)(이하 "BD")의 생명과학 및 진단 솔루션 사업 부문과의 합병 절차를 완료했다고 밝혔다. 이번 합병으로 최고 수준의 기술력과 업계를 선도하는 재무 전망을 갖춘 글로벌 생명과학 및 진단 분야의 선도 기업이 출범하게 되었다. 또한 회사는 Claire M. Fraser 박사의 이사회(이하 "Waters 이사회") 이사 선임을 발표했으며, 이에 따라 Waters 이사회의 구성 인원은 총 11명으로 확대되었다.&
- 김갑성 기자
- 2026-02-13 07:00
SleepAI.com Introduces an AI-Powered Sleep and Emotional Wellness Platform for Modern Life

LOS ANGELES, Feb. 13, 2026 -- SleepAI.com, a personalized AI sleep companion, today announced the launch of an AI-powered sleep and emotional wellness platform, now available on both the iOS and Google Play app stores. The platform is designed to address one of modern life's most persistent challenges: the growing disconnect between how people live and how they sleep. Redefining Sleep Tech: A Custom-Built, End-to-End Intelligent Management Ecosystem SleepAI.com moves beyond traditional sleep apps that rely primarily on static audio content. Instead, the platform delivers
- 김갑성 기자
- 2026-02-13 02:00
Datasea Reports Second Fiscal Quarter 2026 Results

Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a Nevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalization, today announced its unaudited financial results for the second fiscal quarter and the six months ended December 31, 2025. Additional details will be available in the Company's Quarterly Report on Form 10-Q as filed with the SEC. Six Month Fiscal 2026 High
- 김갑성 기자
- 2026-02-12 22:20
Ubie Announces Collaboration to Reinvent the Healthcare Digital Front Door

Ubie and Mayo Clinic collaborate with the goal of delivering a unified, AI-powered chat and voice platform to streamline healthcare access, reduce complexity and offer a best-in-class patient experience Natural conversations, instant answers, and a seamless triage-to-booking flow will drive first-contact resolution, self-scheduling and patient satisfaction scores NEW YORK, Feb. 12, 2026 -- Ubie, an AI-driven and clinically vetted healthcare prediction platform designed to guide patients to the care they need, today announced a collaboration with Mayo Clinic to co-develo
- 김갑성 기자
- 2026-02-12 22:00
Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide

[ 메디채널 김갑성 기자 ] Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 -- On February 8, at the 2026 China New Drug Source Innovation Forum in Shanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten years ago. A decade ago, China's biopharmaceutical innovation ecosystem was still taking shape. Biologics R&D was largely seen as the arena of global pharmaceutical giants. The industry faced significant constraints - immature technologies, limited capital exploration,
- 김갑성 기자
- 2026-02-12 22:00
Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

[ 메디채널 김갑성 기자 ] Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) infants." The approval was supported by data from the pivotal Japan-based JASMINE Phase III clinical trial, a randomised, open-label, parallel-group comparison study in VLBW infants. This first-of-its kind approval set a new regulatory precedent, bridged innovati
- 김갑성 기자
- 2026-02-12 20:00
First clinical success! Yuanhua Tech, with its orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, breaks into the high-end medical equipment market

HONG KONG, Feb. 12, 2026 -- On February 11, the orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, which was 100% homemade by Yuanhua Robotics, Perception and AI Technologies Ltd. (hereinafter referred to as "Yuanhua Tech"), saw its first clinical success at West China Hospital of Sichuan University. This milestone achievement signifies that the domestically produced high-end surgical robot has successfully passed the clinical verification of a top medical institution in the field of self-developed key execution components. It has inject
- 김갑성 기자
- 2026-02-12 19:34
EDAN Connects Clinical Practice and Innovation at 2026 WHX Dubai and WHX Labs Dubai

DUBAI, UAE, Feb. 12, 2026 -- Edan Instruments, Inc. (300206.SZ) participated in WHX Dubai (Formerly Arab Health) and WHX Labs Dubai (Formerly Medlab Middle East), presenting a comprehensive portfolio of medical solutions across multiple clinical disciplines. With an expected attendance of over 235,000 visitors at WHX Dubai and 35,000 at WHX Labs Dubai, the two events brought together healthcare professionals, partners, and industry stakeholders from around the world. This year, WHX Dubai took place at Dubai's newly expanded venue, underscoring its continued growth as an international
- 김갑성 기자
- 2026-02-12 17:27
Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients

ZUG, Switzerland, Feb. 12, 2026 -- Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors. The funding will be used to advance the company's cardiac microcurrent technology and expand its clinical research program. Berlin Heals has developed a novel therapeutic approach for the treatment of heart failure based on its proprietary implantable device, C-MIC (Cardiac Microcurrent). The system h
- 김갑성 기자
- 2026-02-12 16:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 02일 23시 00분